Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease

This study has been completed.
Sponsor:
Information provided by:
Novartis
ClinicalTrials.gov Identifier:
NCT00099242
First received: December 10, 2004
Last updated: December 17, 2007
Last verified: December 2007

December 10, 2004
December 17, 2007
November 2003
Not Provided
  • Change in cognition from baseline at week 24
  • Global clinical impression of change from baseline at week 24
Not Provided
Complete list of historical versions of study NCT00099242 on ClinicalTrials.gov Archive Site
  • Change from baseline at week 24 in activities of daily living
  • Change from baseline at week 24 in behavioral symptoms
  • Change from baseline at week 24 in global cognitive testing
  • Change from baseline at week 24 in executive function
  • Change from baseline at week 24 in attention
Not Provided
Not Provided
Not Provided
 
Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease
Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease

The goal of this research study is to evaluate the safety and efficacy of the rivastigmine transdermal patch in patients with probable Alzheimer's Disease.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
  • Alzheimer's Disease
  • Dementia, Alzheimer Type
Drug: rivastigmine transdermal patch
Not Provided
Alva G, Grossberg GT, Schmitt FA, Meng X, Olin JT. Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses. Int J Geriatr Psychiatry. 2011 Apr;26(4):356-63. doi: 10.1002/gps.2534.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1040
January 2006
Not Provided

Inclusion Criteria:

  • Diagnosis of dementia of the Alzheimer's type
  • Males, and females who are surgically sterile or one year postmenopausal
  • A primary caregiver willing to accept responsibility for supervising the treatment

Exclusion Criteria:

  • Any condition (other than Alzheimer's) that could explain patient's dementia
  • An advanced, severe or unstable disease that may put the patient at special risk
  • Current diagnosis of active, uncontrolled seizure disorder or unstable cardiovascular disease
Both
50 Years to 85 Years
No
Contact information is only displayed when the study is recruiting subjects
United States,   Chile,   Czech Republic,   Denmark,   Finland,   Germany,   Guatemala,   Israel,   Italy,   Korea, Republic of,   Mexico,   Norway,   Peru,   Poland,   Portugal,   Puerto Rico,   Russian Federation,   Slovakia,   Sweden,   Taiwan,   Venezuela
 
NCT00099242
CENA713D2320
Not Provided
Not Provided
Novartis
Not Provided
Not Provided
Novartis
December 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP